ГОСТ Р ИСО 10993-17—2009
Библиография
(1) ИСО 10993-7 Оценка биологического действия медицинских изделий. Часть 7. Остаточное содержание этилен-
оксида после стерилизации
ISO 10993-7, Biological evaluation of medical devices — Part 7: Ethylene oxide steniization residuals
(2) ИСО 14971Устройства медицинские. Применение управления рисками к медицинским устройствам
ISO 14971, Medical devices — Application of risk management to medical devices
(3) LEHMAN. A.J. and FIT2HUGH. O.G. (1954). 100-Fold margin of safety. Association of Food and Drug Officials. U.S.Q.
Bull. 18. pp. 33—35
(4) MUMTA2. M.M. and HERT2BERG. R.C. (1993). The status of interactions data in risk assessment of chemical
mixtures. In J. Saxena. ed. Hazard Assessment of Chemicals. Vol. 8. pp. 47— 79. Hemisphere, Washington. D.C.
(5) MUMTA2. M.M., SIPES. I.G.. CLEWELL, H.J. and YANG. R.S.H. (1993). Risk assessment of chemical mixtures:
Biologic and toxicologic Issues (symposium overview). Fund. Appl. Toxicol. 21. pp. 258—269
(6) Pharmaceutical Manufacturers Association (PMA) (1989). Procedures for setting limits for volatile organic solvents with
methylene chloride as an example of the process. Committee on Rational Specification for Impunties in Bulk Drug
Substances. PMA. Washington. DC. Pharmacopeial Forum 15(6). pp. 5748—5759
(7) Pharmaceutical Manufacturers Association (PMA) (1990). Procedures for setting limits for volatile organic solvents with
chloroform. 1,4-dioxane. ethylene oxide and trichloroethylene as examples of the process. Committee on Rational
Specification for Impurities in Bulk Drug Substances. PMA, Washington. DC. Pharmacopeial Forum 16(3). pp.
541—582
(8) Pharmaceutical Manufacturers Association (PMA) (1991). Procedures for setting limits for volatile organic solvents with
benzene as an example of the process. Committee on Rational Specification for Impurities m Bulk Drug Substances.
PMA, Washington. DC. Pharmacopeial Forum 17(1). pp. 1441 — 1458
(9) United States Pharmacopeial Convention (USP) (2000) Vol. 24. pp. 1877— 1878. <467> Organic volatile Impurities.
USP. Rockville. Maryland
(10} BASKETTER. D.A. (1996). Individual ethnic and seasonal variability In irritant susceptibility of skin: The implications for
a predictive human patch test. Contact Dermatitis 35. pp. 208—213
(11} CONINE. D.. NAUMANN. B. and HECKER, L. (1992). Setting Health-Based Residue Limits For Contaminants in
Pharmaceuticals and Medical Devices. Quality Assurance. Good Practice. Regulation, and the Law. 1(3). pp.
171 — 180
(12) Committee on Carcinogenicity of Chemicals in Food. Consumer Products and the Environment. Guidelines for the
evaluation of chemicals for carcinogenicity. Departmentof Health Report on Health and Social Subjects No. 42. HMSO.
London.1991
(13) DOURSON. M. and STARA. J. (1983). Regulatory history and experimental support for uncertainty (safety) factors.
Reg. Toxicol. Pharmacol. 3 pp. 224—238
(14J CRUMP. K. (1984). A new method for determining allowable daily Intakes. Fund. Appl. Toxicol. 4. pp. 854—871
(15} JUDGE. M.R. (1996). Variation in response of human skin to irritant challenge. Contact Dermatitis 34. pp. 115— 117
(16) LEWIS. S.. LYNCH. J. and NIKIFOROV. A. (1990). A new approach to denvmg community exposure guidelines from
no-observed-adverse-effect level. Reg. Toxicol. Pharmacol. 11. pp. 314—330
(17) KADRY, A.. SKOWRONSKI. G. and ABEL-RAHMAN. M. (1995). Evaluation of the Use of Uncertainty Factors in
Denvmg RfDs for Some Chlorinated Compounds. J. Toxicol. Environ. Health 45. pp. 83—95
(18) SEED. J.. BROWN. R.P. OLIN. R.P. and FORAN. J.A. (1995). Chemical mixtures: Current nsk assessment
methodologies and future directions. Reg. Toxicol. Pharmacol. 22. pp. 76—94
(19) World Health Organization (WHO) (1994). Environmental Health Cnterta 170. Assessing Human Health Risks of
Chemicals: Derivation of Guidance Values for Health-Based Exposure Limits. World Health Organization. Geneva.
Switzerland
20